125 related articles for article (PubMed ID: 24258997)
21. CSPG4-Specific CAR T Cells for High-Risk Childhood B Cell Precursor Leukemia.
Harrer DC; Schuler G; Dörrie J; Schaft N
Int J Mol Sci; 2019 Jun; 20(11):. PubMed ID: 31195686
[TBL] [Abstract][Full Text] [Related]
22. Characterization of monoclonal antibody 155.8 and partial characterization of its proteoglycan antigen on human melanoma cells.
Harper JR; Bumol TF; Reisfeld RA
J Immunol; 1984 Apr; 132(4):2096-104. PubMed ID: 6199423
[TBL] [Abstract][Full Text] [Related]
23. Prospective multi-institutional study of reverse transcriptase polymerase chain reaction for molecular staging of melanoma.
Scoggins CR; Ross MI; Reintgen DS; Noyes RD; Goydos JS; Beitsch PD; Urist MM; Ariyan S; Davidson BS; Sussman JJ; Edwards MJ; Martin RC; Lewis AM; Stromberg AJ; Conrad AJ; Hagendoorn L; Albrecht J; McMasters KM
J Clin Oncol; 2006 Jun; 24(18):2849-57. PubMed ID: 16782924
[TBL] [Abstract][Full Text] [Related]
24. Structural deciphering of the NG2/CSPG4 proteoglycan multifunctionality.
Tamburini E; Dallatomasina A; Quartararo J; Cortelazzi B; Mangieri D; Lazzaretti M; Perris R
FASEB J; 2019 Mar; 33(3):3112-3128. PubMed ID: 30550356
[TBL] [Abstract][Full Text] [Related]
25. Targeting the NG2/CSPG4 proteoglycan retards tumour growth and angiogenesis in preclinical models of GBM and melanoma.
Wang J; Svendsen A; Kmiecik J; Immervoll H; Skaftnesmo KO; Planagumà J; Reed RK; Bjerkvig R; Miletic H; Enger PØ; Rygh CB; Chekenya M
PLoS One; 2011; 6(7):e23062. PubMed ID: 21829586
[TBL] [Abstract][Full Text] [Related]
26. Targeting CSPG4 for isolation of melanoma cell-derived exosomes from body fluids.
Ferrone S; Whiteside TL
HNO; 2020 Feb; 68(2):100-105. PubMed ID: 32006045
[TBL] [Abstract][Full Text] [Related]
27. Immunohistochemical detection of the chondroitin sulfate proteoglycan 4 protein in primary and metastatic melanoma.
Grossauer A; Uranowska K; Kitzwögerer M; Mostegel M; Breiteneder H; Hafner C
Oncol Lett; 2023 Sep; 26(3):382. PubMed ID: 37559576
[TBL] [Abstract][Full Text] [Related]
28. Chondroitin Sulphate Proteoglycan 4 (NG2/CSPG4) Localization in Low- and High-Grade Gliomas.
Mellai M; Annovazzi L; Bisogno I; Corona C; Crociara P; Iulini B; Cassoni P; Casalone C; Boldorini R; Schiffer D
Cells; 2020 Jun; 9(6):. PubMed ID: 32599896
[TBL] [Abstract][Full Text] [Related]
29. Cytokeratin expression in malignant melanoma: potential application of in-situ hybridization analysis of mRNA.
Chen N; Gong J; Chen X; Xu M; Huang Y; Wang L; Geng N; Zhou Q
Melanoma Res; 2009 Apr; 19(2):87-93. PubMed ID: 19190520
[TBL] [Abstract][Full Text] [Related]
30. Detection of melanoma cells in the lymphatic drainage after lymph node dissection in melanoma patients by using two-marker reverse transcriptase-polymerase chain reaction assay.
Włodzimierz R; Rutkowski P; Nowecki ZI; Kulik J; Nasierowska-Guttmejer A; Siedlecki JA
Ann Surg Oncol; 2004 Nov; 11(11):988-97. PubMed ID: 15525828
[TBL] [Abstract][Full Text] [Related]
31. Targeting the melanoma-associated antigen CSPG4 with HLA-C*07:01-restricted T-cell receptors.
Kropp KN; Fatho M; Huduti E; Faust M; Lübcke S; Lennerz V; Paschen A; Theobald M; Wölfel T; Wölfel C
Front Immunol; 2023; 14():1245559. PubMed ID: 37849763
[TBL] [Abstract][Full Text] [Related]
32. Expression of melanoma inhibitory activity in melanoma and nonmelanoma tissue specimens.
Perez RP; Zhang P; Bosserhoff AK; Buettner R; Abu-Hadid M
Hum Pathol; 2000 Nov; 31(11):1381-8. PubMed ID: 11112213
[TBL] [Abstract][Full Text] [Related]
33. Interactions of thrombospondin with sulfated glycolipids and proteoglycans of human melanoma cells.
Roberts DD
Cancer Res; 1988 Dec; 48(23):6785-93. PubMed ID: 3180088
[TBL] [Abstract][Full Text] [Related]
34. Melanoma-associated markers expression in blood: MUC-18 is associated with advanced stages in melanoma patients.
Rapanotti MC; Bianchi L; Ricozzi I; Campione E; Pierantozzi A; Orlandi A; Chimenti S; Federici G; Bernardini S
Br J Dermatol; 2009 Feb; 160(2):338-44. PubMed ID: 19067715
[TBL] [Abstract][Full Text] [Related]
35. Detection of melanoma cells in sentinel lymph nodes by reverse transcriptase-polymerase chain reaction: prognostic significance.
Gradilone A; Ribuffo D; Silvestri I; Cigna E; Gazzaniga P; Nofroni I; Zamolo G; Frati L; Scuderi N; Aglianò AM
Ann Surg Oncol; 2004 Nov; 11(11):983-7. PubMed ID: 15525827
[TBL] [Abstract][Full Text] [Related]
36. Versican is differentially expressed in human melanoma and may play a role in tumor development.
Touab M; Villena J; Barranco C; Arumí-Uría M; Bassols A
Am J Pathol; 2002 Feb; 160(2):549-57. PubMed ID: 11839575
[TBL] [Abstract][Full Text] [Related]
37. Immunohistochemical and molecular analysis of human melanomas for expression of the human cancer-testis antigens NY-ESO-1 and LAGE-1.
Vaughan HA; Svobodova S; Macgregor D; Sturrock S; Jungbluth AA; Browning J; Davis ID; Parente P; Chen YT; Stockert E; St Clair F; Old LJ; Cebon J
Clin Cancer Res; 2004 Dec; 10(24):8396-404. PubMed ID: 15623618
[TBL] [Abstract][Full Text] [Related]
38. Loss of membranous expression of beta-catenin is associated with tumor progression in cutaneous melanoma and rarely caused by exon 3 mutations.
Demunter A; Libbrecht L; Degreef H; De Wolf-Peeters C; van den Oord JJ
Mod Pathol; 2002 Apr; 15(4):454-61. PubMed ID: 11950921
[TBL] [Abstract][Full Text] [Related]
39. Diagnostic value of Sox10 immunohistochemical staining for the detection of metastatic melanoma in sentinel lymph nodes.
Blochin E; Nonaka D
Histopathology; 2009 Nov; 55(5):626-8. PubMed ID: 19912373
[No Abstract] [Full Text] [Related]
40. Ber-H2 (CD30) immunohistochemical staining in malignant melanoma.
Polski JM; Janney CG
Mod Pathol; 1999 Sep; 12(9):903-6. PubMed ID: 10496599
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
